The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...

With an expiration date still more than a year away, here's what the latest details reveal.

News and commentary from the psychiatry world ...

Focus ADHD is an online psychiatric clinic based in Des Moines, Iowa, offering personalized treatment for adult professionals living with ADHD. The clinic provides expert medication management, ...

Please provide your email address to receive an email when new articles are posted on . Asian, Black and Hispanic children with ADHD were less likely to be prescribed medication early vs. white ...

From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.

Women are driving soaring use of ADHD medication, experts say. Researchers from the University of Oxford highlighted a 20-fold rise in use of drugs to manage the condition among w ...

UK had highest relative increase of five countries in study, with 20-fold rise in proportion of women over 25 using it ...

Attention Deficit Hyperactivity Disorder (ADHD) medication use rose threefold over 13 years, with adult women showing the steepest climb.